Business Description
Pulmatrix Inc
NAICS : 325412
SIC : 2834
ISIN : US74584P3010
Total Employee Number:
2Description
Pulmatrix Inc is a biopharmaceutical company focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with important unmet medical needs using its patented dry powder delivery technology, iSPERSE. Its pipeline of clinical assets includes PUR3100 for the treatment of acute migraine, PUR1800 for the treatment of acute exacerbations of chronic obstructive pulmonary disease (AECOPD), and PUR1900 for the treatment of ABPA in patients with asthma and in patients with cystic fibrosis (CF).
Financial Strength
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | No Debt | |||||
Equity-to-Asset | 0.8 | |||||
Interest Coverage | No Debt | |||||
Piotroski F-Score | 2/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 34.6 | |||||
3-Year EPS without NRI Growth Rate | 36 | |||||
3-Year FCF Growth Rate | 35.9 | |||||
3-Year Book Growth Rate | -50.4 |
Momentum Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 27.49 | |||||
9-Day RSI | 41.12 | |||||
14-Day RSI | 47.83 | |||||
3-1 Month Momentum % | 12.8 | |||||
6-1 Month Momentum % | -44.27 | |||||
12-1 Month Momentum % | -77.11 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 4.96 | |||||
Quick Ratio | 4.96 | |||||
Cash Ratio | 3.67 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -0.1 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -90.94 | |||||
ROA % | -81.34 | |||||
ROIC % | -4328.33 | |||||
3-Year ROIIC % | -274.96 | |||||
ROC (Joel Greenblatt) % | -1774.62 | |||||
ROCE % | -92.7 | |||||
Moat Score | 2 | |||||
Tariff Resilience Score | 6 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Forward PE Ratio | 2.71 | |||||
PB Ratio | 2.17 | |||||
Price-to-Tangible-Book | 2.18 | |||||
EV-to-EBIT | 0.82 | |||||
EV-to-EBITDA | 0.82 | |||||
EV-to-Forward-Revenue | 0.33 | |||||
EV-to-FCF | 0.81 | |||||
| Price-to-Net-Current-Asset-Value | 2.18 | |||||
| Price-to-Net-Cash | 2.38 | |||||
Earnings Yield (Greenblatt) % | 121.95 | |||||
FCF Yield % | -81.74 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:PULM
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Pulmatrix Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -1.23 | ||
| Beta | 3.3729 | ||
| 3-Year Sharpe Ratio | 0.26 | ||
| 3-Year Sortino Ratio | 0.68 | ||
| Volatility % | 86.22 | ||
| 14-Day RSI | 47.83 | ||
| 14-Day ATR ($) | 0.126519 | ||
| 20-Day SMA ($) | 1.642 | ||
| 12-1 Month Momentum % | -77.11 | ||
| 52-Week Range ($) | 1.16 - 6.4932 | ||
| Shares Outstanding (Mil) | 3.65 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Pulmatrix Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Pulmatrix Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-10-16 | In 92 days | ||
| Second quarter earnings results for 2026 | 2026-08-06 | In 21 days | ||
| General meeting for 2025 | 2026-07-16 | 1.62 (+0.00%) | ||
| First quarter earnings results for 2026 | 2026-05-15 | 1.27 (-2.68%) | ||
| Annual report for 2025 | 2026-02-26 | 3.21 (-4.75%) | ||
| Fourth quarter earnings results for 2026 | 2026-02-26 | 3.21 (-4.75%) | ||
| Third quarter earnings results for 2025 | 2025-10-16 | 4.76 (-4.65%) | ||
| Second quarter earnings results for 2025 | 2025-08-06 | 5.48 (+1.29%) | ||
| First quarter earnings results for 2025 | 2025-05-15 | 6.12 (-4.13%) | ||
| Annual report for 2024 | 2025-03-21 | 7.60 (-2.19%) |
Show
Entries
Pulmatrix Inc Frequently Asked Questions
What is Pulmatrix Inc(PULM)'s stock price today?
The current price of PULM is $1.57. The 52 week high of PULM is $6.49 and 52 week low is $1.16.
When is next earnings date of Pulmatrix Inc(PULM)?
The next earnings date of Pulmatrix Inc(PULM) is 2026-08-06 Est..
Does Pulmatrix Inc(PULM) pay dividends? If so, how much?
Pulmatrix Inc(PULM) does not pay dividend.
Guru Commentaries on NAS:PULM
No articles.
Press Release
Articles on Pulmatrix Inc
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers